ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Genmab and Zai Lab side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GenmabZai Lab
studies on the registry7732
open to participants now159
phase 3 studies under way174
reach primary completion within a year95
programswith a study of their own in two years94

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGenmabZai Lab
Phase 1

Genmab: 4 of its 9 programs at phase 1

  1. Anti-SLITRK6 Antibody-drug Conjugate GEN1106phase 1
  2. Bispecific Antibody GEN1079phase 1
  3. GEN1119phase 1
  4. GEN3018phase 1
44%

Zai Lab: 2 of its 4 programs at phase 1

  1. ZL-1503phase 1
  2. Anti-LRRC15 Antibody-drug Conjugate ZL-6201phase 1
50%
Phase 2

Genmab: 1 of its 9 programs at phase 2

  1. GEN1078phase 2
11%
00%
Phase 3

Genmab: 4 of its 9 programs at phase 3

  1. epcoritamabphase 3
  2. rinatabart sesutecanphase 3
  3. petosemtamabphase 3
  4. acasunlimabphase 3
44%

Zai Lab: 2 of its 4 programs at phase 3

  1. Zocilurtatug Pelitecanphase 3
  2. elegrobartphase 3
50%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Genmab3 readouts · 2 phase 3····

Genmab, Mar ’27: 1 program whose next study reaches primary completion

  1. epcoritamabphase 3 · Mar 0 · NCT05451810
···

Genmab, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acasunlimabphase 3 · Jul 30 · NCT06635824
·

Genmab, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rinatabart sesutecanphase 3 · Sep 0 · NCT07604766
·
Zai Lab3 readouts · 1 phase 3···

Zai Lab, Feb ’27: 1 program whose next study reaches primary completion

  1. ZL-1503phase 1 · Feb 6 · NCT07658482

Zai Lab, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elegrobartphase 3 · Mar 14 · NCT07211776
·

Zai Lab, May ’27: 1 program whose next study reaches primary completion

  1. Zocilurtatug Pelitecanphase 3 · May 30 · NCT06179069
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Genmab

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Zai Lab

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Genmab 5 of 9 · Zai Lab 2 of 4 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.